AIS's Health Business Daily is a daily email newsletter with strategic business stories written by experienced AIS Health reporters, as well as other information of interest to health care business leaders — including news from the nation’s leading health insurers, developments from the federal and state governments that impact the health care industry, and exclusive datapoints from Subscribe now to get an issue delivered to your inbox every morning!
May 9, 2017

Hot Topic

Here’s a look at insurers’ efforts to manage costs and utilization for new drugs coming on the market:

FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now
In late March, the FDA went on an approval tear, paving the way for multiple anticipated specialty drugs to come onto the U.S. market....

Auvi-Q Prepares to Launch at Zero Cost to Most Patients, but Payers Footing the Bill
The manufacturer of an insulin autoinjector is once again in the crosshairs of a public that is growing more and more exasperated with the high prices of drugs....

How Should Payers Be Preparing For Biosimilar Remicade Launch?
The second FDA-approved biosimilar to hit the U.S. market, Inflectra (infliximab-dyyb), will launch at a 15% discount to the wholesale acquisition cost of Janssen Biotech, Inc.’s reference drug Remicade (infliximab)....

Today's AIS Health Datapoint

5.4 million ... is the number of consumers whose incomes fall between 100% and 200% of the federal poverty level who selected marketplace plans on federally facilitated exchanges. In the 39 states using the federal platform, nearly 135,000 people per state, on average, fall into this range.


            Check out a demo of AIS Health's Health Insurance Exchange Database

Quote of the Day

“[The debate over drug pricing] is definitely more intense, vocal and louder than usual, primarily out of fear. All stakeholders can’t figure out what’s happening in D.C., so they are trying to divert attention away from their role and financial stake in pharma and accuse someone else of profiteering. There’s a sense someone’s ox is going to be gored, and that’s a painful fate to contemplate.”

— Joseph Paduda, principal at Health Strategy Associates, LLC, tells Health Plan Week

Click here to read the HEALTH PLAN WEEK article in which this quote appeared — "PhRMA Ad Campaign Calls Out Health Insurers, Urges Them to Share Rebates" (Free for HPW subscribers; $17 for non-subscribers.)


Advertise with AISThe Featured Story of the day may be accessed on the day it is transmitted without logging in to Thereafter, you may need to log in to access the Featured Story. If you haven’t yet registered on, please take a minute to create a free account now and get free access to thousands of articles, blogs and much more.

Content questions or suggestions should be directed to Executive Editor Jill Brown at If you are interested in advertising in AIS's HEALTH BUSINESS DAILY, please contact BJ Taylor at

AIS's HEALTH BUSINESS DAILY is copyrighted and protected by federal law. The re-use of its content is restricted (see below). However, you are permitted to forward this email to as many of your friends and colleagues as you wish, or better yet have them sign up for their own copy at atlantic_subscription.cfm

Copyright © 2017 Managed Markets Insight & Technology, LLC. All rights reserved. It is not permissible to include all or any portion of this content on any Web site, intranet or electronic network or in any print publication, without AIS's written permission in advance. Permission requests should be directed to

With archives of AIS's Health Business Daily, features like the News Archives, AIS Blogs and more! (Free registration required)

Visit AIS Health on: AISHealth  Follow AISHealth on Twitter  Follow AISHealth on Facebook  Follow AISHealth on LinkedIn